Zomedica targets 2020 launch for three diagnostics

摘要

Zomedica Pharmaceuticals plans to begin marketing three of its diagnostics in the US over the course of 2020.Zomedica expects the cost of these assays for pet owners "will only be a fraction of the cost of current methods of testing, which can sometimes equate to thousands of dollars depending on the presentation".The company is also developing assays for the detection of hemangiosarcoma and osteosarcoma for use with its liquid biopsy platform - ZM-017. Lymphoma, hemangiosarcoma and osteosarcoma are three of the top five most regularly diagnosed aggressive canine cancers.